As shown in Table 2, subjects with a diagnosis of PC carrying a CDC73 gene mutation (PCCDC73+) had a significantly lower AaO mean than PC controls affected by the same type of tumor but negative at the molecular screening (PCCDC73–): 39.15 ± 14.68 vs. 53.00 ± 15.66 years (p = 0.017), respectively, as well as for subjects with AA carrying (AACDC73+) or not (AACDC73–) a CDC73 gene mutation: 28.00 ± 18.46 vs. 53.86 ± 19.02 years, (p = 0.005), respectively. The gene discussed is CDC73; the disease is neoplasm.